Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 Marijuana and Psychedelic Stock News stories for the week of April 6th – 12th, 2020.
Without further ado, let’s get started.
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496) announced it has entered into a definitive agreement to acquire 100% of AltMed Capital Corp. AltMed is a preeminent Canadian Ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer. AltMed’s Psychedelics clinic is licensed by Health Canada to dose eligible patients with Psilocybin and is the only clinic in Canada able to perform Psilocybin doses under Health Canada approval.
Horizons ETFs Management (Canada) recently completed the quarterly rebalance of its cannabis-focused ETFs Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ) and Horizons U.S. Marijuana Index ETF (NEO: HMUS). Following the rebalance, here’s what the two Cannabis ETFs look like now.
Thanks to recent advancements in psychedelic medicine, there’s renewed hope and optimism surrounding the deadly opioid epidemic. ATAI Life Sciences, DemeRx and MindMed (NEO: MMED) (OTC: MMEDF) (FRA: BGHM) are waging war against opioid addiction By utilizing this one little-known Psychedelic substance.
It seems that it’s all over for CannTrust Holdings (TSX: TRST) (NYSE: CTST) shareholders. The company confirmed within a news release that its equity will be delisted from the major exchanges, and that a cease trade order will remain on the equity.
Trulieve (CSE: TRUL) (OTCQX: TCNNF) announced earnings this week for the fourth quarter and full fiscal year 2019. The top U.S. multi-state operator (MSO) posted 2019 total revenue of $252.8 million, up 145% year-over-year.
Look for leading U.S. multi-state operator (MSO) Green Thumb Industries (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) to keep outperforming its peers in these tough market conditions, said Echelon Wealth Partners analyst Andrew Semple in a new report to clients.
If 2019 was a tough year for the cannabis industry, 2020 could be downright catastrophic. However, as bad as things look today, the industry may get stronger as a result of the COVID-19 pandemic. Here are three ways the Marijuana Stocks may actually get stronger as a result of the coronavirus.
According to Wall Street, the following four Canadian Cannabis Stocks are on the fast track to becoming profitable in 2021: Organigram (TSX: OGI) (NASDAQ: OGI) (FRA: 0OG), Aphria (TSX: APHA) (NYSE: APHA) (FRA: 10E), MediPharm Labs (TSX: LABS) (OTCQX: MEDIF) (FRA: MLZ) and Valens (TSXV: VLNS) (OTCQX: VGWCF) (FRA: 7LV).
In an update to clients, Stanley reiterated his “Buy” rating and $36 target price, saying Trulieve (CSE: TRUL) (OTCQX: TCNNF) has one of the best balance sheets in the industry.
GW Pharmaceuticals (NASDAQ: GWPH) (FRA: GW2A) confirmed it has obtained a notice from the Drug Enforcement Administration (DEA) certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance.